Gaze Contingent Feedback in Major Depressive Disorder (MDD)

Tel Aviv University60 enrolled

Overview

The purpose of this study is to determine whether giving gaze-contingent feedback is an effective attention modification procedure, helping in the treatment of Major Depressive Disorder (MDD)

The study examines giving depressive participants gaze-contingent feedback as a novel attention training procedure. Half of the participants will receive contingent feedback while the other half would receive non-contingent "placebo" feedback.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

Conditions

Depression, Unipolar Depressive Disorder Depressive Disorder, Major

Interventions

Attention ModificationBEHAVIORAL

Feedback according to participants' viewing patterns, in order to modify their attention.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * A signed consent form * Men and women between the ages of 18 and 65. * Meeting a current diagnosis of Major Depressive Disorder (MDD) according to the DSM-IV * MDD as the primary diagnosis: In cases of co-morbidity, MDD will be deemed as the most distressing and clinically significant condition among the co-morbid disorders * Stable pharmaco-therapy: Participants receiving a pharmacological treatment who are taking a stable medication for at least 3 months before the beginning of the procedure. Exclusion Criteria: * Psychotic episode in the past or the present time. * Co-morbidity with any neurological disorder (i.e., epilepsy, brain injury). * Another psychotherapeutic treatment during the study. * Usage of neuroleptic medication. * Change in medication status during the study. * Substantial usage of drugs or alcohol in the present time. * Poor judgment capacity (i.e., children under 18 and special populations). * High Risk of Suicide.

Locations (1)

Tel-Aviv University

Tel Aviv, Israel

Outcomes

Primary Outcomes

Change from baseline - Structured Interview for the Montgomery-Asberg Depression Rating Scale (SIGMA)

The SIGMA is a ten-item diagnostic structured interview which psychiatrists use to measure the severity of depressive episodes in patients with mood disorders. Each item is rated on scale ranging from 0 to 6 with a possible total score of 60, with regard to the passing week.

Time frame: post treatment (1 week after treatment completion) and 3-month follow up

Secondary Outcomes

Change from baseline - BDI-II - Beck Depression Inventory

The BDI -II is a 21-question multiple-choice self-report inventory. Each item is rated on scale ranging from 0 to 3, Higher total scores indicate more severe depressive symptoms.

Time frame: post treatment (1 week after treatment completion) and 3-month follow up

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.